Alimera Sciences, Inc. (NASDAQ:ALIM)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Friday. They currently have a $5.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 300.00% from the company’s current price.

A number of other equities research analysts have also weighed in on ALIM. Zacks Investment Research upgraded Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Monday, July 10th. Cowen and Company reiterated a “buy” rating and issued a $3.00 target price on shares of Alimera Sciences in a research report on Tuesday, July 11th. Finally, ValuEngine upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Alimera Sciences currently has an average rating of “Hold” and a consensus target price of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) traded up 0.81% on Friday, reaching $1.25. 112,499 shares of the company’s stock traded hands. Alimera Sciences has a 12-month low of $1.03 and a 12-month high of $1.72. The firm’s market cap is $86.31 million. The stock has a 50-day moving average of $1.36 and a 200 day moving average of $1.42.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. The business’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, equities research analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/27/alimera-sciences-inc-alim-receives-buy-rating-from-hc-wainwright.html.

Several institutional investors and hedge funds have recently modified their holdings of the business. KCG Holdings Inc. grew its holdings in shares of Alimera Sciences by 127.0% during the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 43,977 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Alimera Sciences by 24.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 35,200 shares during the period. Kennedy Capital Management Inc. purchased a new position in Alimera Sciences during the 1st quarter valued at about $467,000. Finally, JW Asset Management LLC boosted its holdings in Alimera Sciences by 15.6% during the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after acquiring an additional 130,000 shares during the period. 37.20% of the stock is owned by institutional investors and hedge funds.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.